glp-1 drugs shortage FDA says that the is over GLP-1 No Longer on FDA's

Introduced in the twenty-first century, glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a class of antidiabetic drugs noted not only for their potent glucose-lowering effects but also for their cardiovascular and renal protective benefits

In late April 2025, the FDA issued a key update regarding the use of compounded GLP-1 receptor agonists like semaglutide and tirzepatide

Obesity is a chronic disease associated with many complications

Support for weight management goals

Agents such as dulaglutide, liraglutide, semaglutide, and tirzepatide differ in pharmacology and dosing, directly influencing perioperative safety, particularly due to their effects on gastric motility and the high frequency of gastrointestinal (GI) adverse events that raise concerns about aspiration and postoperative morbidity in urgent or elective procedures

Type 2 Diabetes Mellitus (T2DM) is one of the most common metabolic disorders worldwide